Drugs List

Therapeutic Indications

Uses

Pre-anaesthetic medication

Analgesia during anaesthesia

Obstetric analgesia

Management of moderate to severe pain

Not all brands are licensed for all indications

Administration

Solution for injection for intramuscular, intravenous or subcutaneous administration.

Handling

Solution for injection

For single use only. Any unused portion should be discarded.

The injection should be administered immediately after the ampoule is opened.

Reconstitution

For slow intravenous administration, the solution for injection may be diluted to 10ml with Water for Injections.

Following dilution, chemical and physical in-use stability has been demonstrated for 24 hours at 25 degrees C.
If not used immediately, the in-use storage times and conditions prior to use are the responsibility of the user. These would not normally be for longer than 24 hours at 2 - 8 degrees C, unless dilution occurred under controlled and validated aseptic conditions.

Incompatibilities

Pethidine solution for injection is incompatible with the following:
Aminophylline
Barbiturates
Heparin sodium
Hydrocortisone sodium succinate
Methicillin sodium
Methyl prednisolone succinate
Morphine sulfate
Phenytoin sodium
Sodium bicarbonate
Sodium iodide
Sulfadiazine sodium
Thiamylal sodium
Aciclovir sodium
Imipenem
Furosemide
Idarubicin
Potassium iodide
Liposomal doxorubicin hydrochloride

Contraindications

Coma

Acute respiratory depression

Obstructive airways disease

Acute asthma

Respiratory insufficiency

Within 2 weeks of discontinuing MAOI's

Acute alcoholism

Increased intracranial pressure

Convulsive disorders

Paralytic ileus
Risk of paralytic ileus

Head injury

Severe renal impairment

Severe hepatic impairment

Phaeochromocytoma

Delirium tremens

Supraventricular tachycardia

Diabetic acidosis

Within 7 days of discontinuing safinamide

Precautions and Warnings

Treatment should be supervised by a specialist.

Use with caution and reduce dose if necessary in patients with the following conditions:
Mild to moderate renal impairment - see Dosage; Renal Impairment
Mild to moderate hepatic impairment - see Dosage; Hepatic Impairment
Biliary tract disorders
Hypotension
Hypothyroidism - reduce dose
Adreno-cortical insufficiency - reduce dose
Shock
Prostatic hypertrophy
Inflammatory bowel disorders
Obstructive bowel disorders
Myasthenia gravis
Cardiac arrhythmias
Severe cor pulmonale
Asthma
Reduced respiratory reserve
History of convulsive disorders
Elderly - see Dosage; Elderly
Children - see Dosage; Children
Neonates and premature infants

Pethidine neurotoxicity may occur in patients with renal failure, cancer or sickle cell anaemia if concurrent anticholinergics are administered or during prolonged administration of increasing pethidine doses.

Use with caution in debilitated patients. A reduction in dosage may be advisable in these patients.

Use with caution in patients with drug addiction or a history of drug addiction.

Pregnancy - see Pregnancy section

Breastfeeding - see Lactation section

Repeated use can lead to tolerance and dependence. Withdrawal symptoms may occur on cessation of therapy, therefore abrupt withdrawal should be avoided.

Pethidine may cause drowsiness. The ability to drive or operate machinery may be severely affected during and for some time after the administration of pethidine. If affected patients should be advised not to drive or operate machinery.

Not all available brands are licensed for all indications.

Pregnancy and Lactation

Pregnancy

The manufacturer advises that pethidine may only be administered during pregnancy if the expected benefits outweigh the potential risks.

Safety of pethidine administration during pregnancy has not been adequately established. However, this product has been widely used for many years without apparent ill consequence, and epidemiologic studies have not uncovered an association between use during the first trimester and congenital malformations. Animal studies have not shown any hazard associated with pethidine.

Pethidine crosses the placenta rapidly during pregnancy. It can reach higher foetal concentrations than in maternal serum due to the limited metabolic capacity of the foetus: pethidine is decomposed slowly and has a considerably lengthened half-life of 18 hours, compared to 3-4 hours in adults.

Administration during labour may cause respiratory depression in the neonate and gastric stasis and inhalation pneumonia in the mother. However, Schaefer states that pethidine is the analgesic of choice during labour as labour is not lengthened, the strength of contractions is not diminished, and neither the severity of bleeding or the involution of the uterus is influenced. Neonates may experience withdrawal symptoms if the mother is dependent on pethidine.

Schaefer concludes that although use as an analgesic during pregnancy is not recommended, inadvertent use does not require either a termination or additional diagnostic procedures.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

The manufacturer advises that pethidine may only be administered during breastfeeding if the expected benefits outweigh the potential risks.

Pethidine is excreted in breast milk. No adverse effects in nursing infants were reported in studies of mothers who had received pethidine during labour. However, the long half-life of pethidine and its metabolite may result in neonatal plasma accumulation, especially in premature infants. Schafer recommends that pethidine is acceptable if necessary, but because of its depressive effect on respiration, particular care should be taken with children with a tendency towards apnoea. A physician should be contacted immediately if the neonate shows signs of increased sleepiness, difficulty breastfeeding, breathing difficulties or limpness.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Side Effects

Respiratory depression
Sedation
Nausea
Constipation
Dizziness
Vomiting
Sweating
Tolerance
Anaphylactic reaction
Orthostatic hypotension
Facial flushing
Bradycardia
Palpitations
Tachycardia
Vertigo
Loss of mental acuity
Confusion
Mood changes
Dysphoria
Euphoria
Restlessness
Hallucinations
Headache
Miosis
Blurred vision
Double vision
Visual disturbances
Dry mouth
Biliary spasm
Urticaria
Pruritus
Rash
Injection site reactions
Urinary retention
Difficulty in micturition
Ureteric spasm
Anti-diuretic effect
Dependence
Hypotension
CNS excitation
Hypothermia
Reduced libido
Reduction of male potency
Drowsiness
Hypersensitivity
Tremor
Convulsions
Fainting
Decreased corneal reflex
Dry eye
Hypertension
Muscle twitch
Renal colic
Sexual dysfunction
Weakness
Muscle rigidity
Oedema
Sleep disturbances
Agitation
Delirium
Syncope
Vasodilatation

Presentation

Solution for injection containing pethidine hydrochloride 100mg in10ml
Solution for injection containing pethidine hydrochloride 50mg in 5ml

Solution for injection containing pethidine hydrochloride 100mg in 2ml
Solution for injection containing pethidine hydrochloride 50mg in1ml

Drugs List

Therapeutic Indications

Uses

Pre-anaesthetic medication

Analgesia during anaesthesia

Obstetric analgesia

Management of moderate to severe pain

Not all brands are licensed for all indications

Dosage

Treatment should be supervised by a specialist.

Adults

Elderly

Children

Patients with Renal Impairment

Patients with Hepatic Impairment

Administration

Solution for injection for intramuscular, intravenous or subcutaneous administration.

Handling

Solution for injection

For single use only. Any unused portion should be discarded.

The injection should be administered immediately after the ampoule is opened.

Reconstitution

For slow intravenous administration, the solution for injection may be diluted to 10ml with Water for Injections.

Following dilution, chemical and physical in-use stability has been demonstrated for 24 hours at 25 degrees C.
If not used immediately, the in-use storage times and conditions prior to use are the responsibility of the user. These would not normally be for longer than 24 hours at 2 - 8 degrees C, unless dilution occurred under controlled and validated aseptic conditions.

Incompatibilities

Pethidine solution for injection is incompatible with the following:
Aminophylline
Barbiturates
Heparin sodium
Hydrocortisone sodium succinate
Methicillin sodium
Methyl prednisolone succinate
Morphine sulfate
Phenytoin sodium
Sodium bicarbonate
Sodium iodide
Sulfadiazine sodium
Thiamylal sodium
Aciclovir sodium
Imipenem
Furosemide
Idarubicin
Potassium iodide
Liposomal doxorubicin hydrochloride

Contraindications

Coma

Acute respiratory depression

Obstructive airways disease

Acute asthma

Respiratory insufficiency

Within 2 weeks of discontinuing MAOI's

Acute alcoholism

Increased intracranial pressure

Convulsive disorders

Paralytic ileus
Risk of paralytic ileus

Head injury

Severe renal impairment

Severe hepatic impairment

Phaeochromocytoma

Delirium tremens

Supraventricular tachycardia

Diabetic acidosis

Within 7 days of discontinuing safinamide

Precautions and Warnings

Treatment should be supervised by a specialist.

Use with caution and reduce dose if necessary in patients with the following conditions:
Mild to moderate renal impairment - see Dosage; Renal Impairment
Mild to moderate hepatic impairment - see Dosage; Hepatic Impairment
Biliary tract disorders
Hypotension
Hypothyroidism - reduce dose
Adreno-cortical insufficiency - reduce dose
Shock
Prostatic hypertrophy
Inflammatory bowel disorders
Obstructive bowel disorders
Myasthenia gravis
Cardiac arrhythmias
Severe cor pulmonale
Asthma
Reduced respiratory reserve
History of convulsive disorders
Elderly - see Dosage; Elderly
Children - see Dosage; Children
Neonates and premature infants

Pethidine neurotoxicity may occur in patients with renal failure, cancer or sickle cell anaemia if concurrent anticholinergics are administered or during prolonged administration of increasing pethidine doses.

Use with caution in debilitated patients. A reduction in dosage may be advisable in these patients.

Use with caution in patients with drug addiction or a history of drug addiction.

Pregnancy - see Pregnancy section

Breastfeeding - see Lactation section

Repeated use can lead to tolerance and dependence. Withdrawal symptoms may occur on cessation of therapy, therefore abrupt withdrawal should be avoided.

Pethidine may cause drowsiness. The ability to drive or operate machinery may be severely affected during and for some time after the administration of pethidine. If affected patients should be advised not to drive or operate machinery.

Not all available brands are licensed for all indications.

Pregnancy and Lactation

Pregnancy

The manufacturer advises that pethidine may only be administered during pregnancy if the expected benefits outweigh the potential risks.

Safety of pethidine administration during pregnancy has not been adequately established. However, this product has been widely used for many years without apparent ill consequence, and epidemiologic studies have not uncovered an association between use during the first trimester and congenital malformations. Animal studies have not shown any hazard associated with pethidine.

Pethidine crosses the placenta rapidly during pregnancy. It can reach higher foetal concentrations than in maternal serum due to the limited metabolic capacity of the foetus: pethidine is decomposed slowly and has a considerably lengthened half-life of 18 hours, compared to 3-4 hours in adults.

Administration during labour may cause respiratory depression in the neonate and gastric stasis and inhalation pneumonia in the mother. However, Schaefer states that pethidine is the analgesic of choice during labour as labour is not lengthened, the strength of contractions is not diminished, and neither the severity of bleeding or the involution of the uterus is influenced. Neonates may experience withdrawal symptoms if the mother is dependent on pethidine.

Schaefer concludes that although use as an analgesic during pregnancy is not recommended, inadvertent use does not require either a termination or additional diagnostic procedures.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

The manufacturer advises that pethidine may only be administered during breastfeeding if the expected benefits outweigh the potential risks.

Pethidine is excreted in breast milk. No adverse effects in nursing infants were reported in studies of mothers who had received pethidine during labour. However, the long half-life of pethidine and its metabolite may result in neonatal plasma accumulation, especially in premature infants. Schafer recommends that pethidine is acceptable if necessary, but because of its depressive effect on respiration, particular care should be taken with children with a tendency towards apnoea. A physician should be contacted immediately if the neonate shows signs of increased sleepiness, difficulty breastfeeding, breathing difficulties or limpness.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Effects on Ability to Drive and Operate Machinery

This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988 (England and Wales). When prescribing this medicine: Advise patient the medicine can affect cognitive function and is likely to affect ability to drive. Advise patient not to drive until they know how the medicine affects them.

Counselling

Advise patients that their ability to drive and operate machinery may be impaired by treatment.

Side Effects

Respiratory depression
Sedation
Nausea
Constipation
Dizziness
Vomiting
Sweating
Tolerance
Anaphylactic reaction
Orthostatic hypotension
Facial flushing
Bradycardia
Palpitations
Tachycardia
Vertigo
Loss of mental acuity
Confusion
Mood changes
Dysphoria
Euphoria
Restlessness
Hallucinations
Headache
Miosis
Blurred vision
Double vision
Visual disturbances
Dry mouth
Biliary spasm
Urticaria
Pruritus
Rash
Injection site reactions
Urinary retention
Difficulty in micturition
Ureteric spasm
Anti-diuretic effect
Dependence
Hypotension
CNS excitation
Hypothermia
Reduced libido
Reduction of male potency
Drowsiness
Hypersensitivity
Tremor
Convulsions
Fainting
Decreased corneal reflex
Dry eye
Hypertension
Muscle twitch
Renal colic
Sexual dysfunction
Weakness
Muscle rigidity
Oedema
Sleep disturbances
Agitation
Delirium
Syncope
Vasodilatation

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Shelf Life and Storage

Do not store above 25 degrees C
Keep in the outer carton

Further Information

Last Full Review Date: July 2011

Reference Sources

Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 8th edition (2008) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.

Summary of Product Characteristics: Pethidine Injection 50mg/ml. Auden McKenzie Ltd. Revised July 2010
Summary of Product Characteristics: Pethidine Injection 1%. Martindale Pharmaceuticals. Revised July 2008
Summary of Product Characteristics: Pethidine Injection 5%. Martindale Pharmaceuticals. Revised October 2009
Summary of Product Characteristics: Pethidine Injection. Goldshield. Revised April, 2008

Gov.uk. Government departments. Department for Transport. Publications. Drug driving and medicine: advice for healthcare professionals. Drug driving: Guidance for healthcare professionals on drug driving. Available at: https://www.gov.uk Last accessed: 6 January 2015
New drug driving offence implications for medicines packaging. Medicines Regulatory News. 10 December 2013. Available at: https://www.mhra.gov.uk Last accessed: 6 January 2015

NICE Evidence Services Available at: www.nice.org.uk Last accessed: 14 September 2017

US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Meperidine - Record 365. Last revised: July 5, 2011
Last accessed: July 19, 2011